Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788111 | 0.91 | BAZ2B (0.47) | KMT2ALMNAMEN1HTTL3MBTL1 | |
| SCHEMBL17462541 | 0.85 | L3MBTL1 (0.46) | KMT2ALMNAMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5442760 | 0.84 | LMNA (0.47) | KMT2ALMNAMEN1HTTL3MBTL1 | |
| SCHEMBL17462528 | 0.84 | L3MBTL1 (0.45) | KMT2ALMNAMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5780558 | 0.83 | ESR1 (0.43) | KMT2ALMNAMEN1HTTL3MBTL1 | |
| SCHEMBL25307344 | 0.78 | ESR2 (0.52) | KMT2ALMNAMEN1HTTL3MBTL1 | |
| SCHEMBL31034811 | 0.78 | ESR2 (0.52) | KMT2ALMNAMEN1HTTL3MBTL1 | |
| SCHEMBL29310346 | 0.78 | ESR2 (0.52) | KMT2ALMNAMEN1HTTL3MBTL1 | |
| SCHEMBL2310023 | 0.77 | ALDH1A1 (0.55) | KMT2ALMNAMEN1ALDH1A1HPGD | |
| SCHEMBL29310313 | 0.76 | LMNA (0.45) | KMT2ALMNAMEN1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2016014463-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | WO | disclosed |
| US-20070043026-A1 | Dopamine receptor modulators as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1487801-B1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO¬D|AZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-20050222124-A1 | Benzenesulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20050090485-A1 | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1503989-A1 | DOPAMINE RECEPTOR MODULATORS AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-1474399-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003095428-A1 | DOPAMINE RECEPTOR MODULATORS AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003068752-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ADCY9, ADCY7, GUCY1B1 | KMT2A 3415/4885LMNA 1564/4885MEN1 1764/4885 |
| US-20050090485-A1 | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders | HTR6, HTR7, HTR2A | KMT2A 1786/4885LMNA 3284/4885MEN1 2488/4885 |
| US-20070043026-A1 | Dopamine receptor modulators as antipsychotic agents | SIGMAR1, CHRM1, OPRM1 | KMT2A 3323/4885LMNA 4341/4885MEN1 1718/4885 |
| US-20050222124-A1 | Benzenesulfonamide derivatives as antipsychotic agents | SIGMAR1, CNR1, CBR1 | KMT2A 2679/4885LMNA 2723/4885MEN1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.